These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

366 related items for PubMed ID: 10726922

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
    Kurosaki E, Nakano R, Shimaya A, Yoshida S, Ida M, Suzuki T, Shibasaki M, Shikama H.
    Biochem Pharmacol; 2003 Mar 01; 65(5):795-805. PubMed ID: 12628477
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological profiles of a novel oral antidiabetic agent, JTT-501, an isoxazolidinedione derivative.
    Shibata T, Matsui K, Nagao K, Shinkai H, Yonemori F, Wakitani K.
    Eur J Pharmacol; 1999 Jan 08; 364(2-3):211-9. PubMed ID: 9932726
    [Abstract] [Full Text] [Related]

  • 4. Effects of KY-903, a Novel Tetrazole-Based Peroxisome Proliferator-Activated Receptor γ Modulator, in Male Diabetic Mice and Female Ovariectomized Rats.
    Ito Y, Yamamoto M, Furukawa S, Fukui M, Morishita K, Kitao T, Shirahase H.
    Biol Pharm Bull; 2021 Jan 08; 44(5):659-668. PubMed ID: 33952822
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. YM440, a novel hypoglycemic agent, protects against nephropathy in Zucker fatty rats via plasma triglyceride reduction.
    Nakano R, Kurosaki E, Shimaya A, Kajikawa S, Shibasaki M.
    Eur J Pharmacol; 2006 Nov 07; 549(1-3):185-91. PubMed ID: 16989806
    [Abstract] [Full Text] [Related]

  • 7. Comparison of the antidiabetic effects of brain-derived neurotrophic factor and thiazolidinediones in obese diabetic mice.
    Yamanaka M, Itakura Y, Tsuchida A, Nakagawa T, Noguchi H, Taiji M.
    Diabetes Obes Metab; 2007 Nov 07; 9(6):879-88. PubMed ID: 17924870
    [Abstract] [Full Text] [Related]

  • 8. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
    Mori Y, Murakawa Y, Okada K, Horikoshi H, Yokoyama J, Tajima N, Ikeda Y.
    Diabetes Care; 1999 Jun 07; 22(6):908-12. PubMed ID: 10372240
    [Abstract] [Full Text] [Related]

  • 9. Troglitazone action is independent of adipose tissue.
    Burant CF, Sreenan S, Hirano K, Tai TA, Lohmiller J, Lukens J, Davidson NO, Ross S, Graves RA.
    J Clin Invest; 1997 Dec 01; 100(11):2900-8. PubMed ID: 9389757
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of troglitazone on body fat distribution in type 2 diabetes.
    Akazawa S, Sun F, Ito M, Kawasaki E, Eguchi K.
    Diabetes Care; 2000 Aug 01; 23(8):1067-71. PubMed ID: 10937499
    [Abstract] [Full Text] [Related]

  • 11. Alteration in expression profiles of a series of diabetes-related genes in db/db mice following treatment with thiazolidinediones.
    Suzuki A, Yasuno T, Kojo H, Hirosumi J, Mutoh S, Notsu Y.
    Jpn J Pharmacol; 2000 Oct 01; 84(2):113-23. PubMed ID: 11128033
    [Abstract] [Full Text] [Related]

  • 12. The novel hypoglycemic agent YM440 improves hepatic insulin resistance in obese Zucker fatty rats.
    Nakano R, Kurosaki E, Shimaya A, Shibasaki M.
    J Pharmacol Sci; 2006 Aug 01; 101(4):311-7. PubMed ID: 16891767
    [Abstract] [Full Text] [Related]

  • 13. Insulin resistance and its treatment by thiazolidinediones.
    Lebovitz HE, Banerji MA.
    Recent Prog Horm Res; 2001 Aug 01; 56():265-94. PubMed ID: 11237217
    [Abstract] [Full Text] [Related]

  • 14. Thiazolidinediones--the new insulin enhancers.
    Jha RJ.
    Clin Exp Hypertens; 1999 Aug 01; 21(1-2):157-66. PubMed ID: 10052651
    [Abstract] [Full Text] [Related]

  • 15. Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats.
    Fujiwara T, Yoshioka S, Yoshioka T, Ushiyama I, Horikoshi H.
    Diabetes; 1988 Nov 01; 37(11):1549-58. PubMed ID: 3053303
    [Abstract] [Full Text] [Related]

  • 16. Troglitazone prevents and reverses dyslipidemia, insulin secretory defects, and histologic abnormalities in a rat model of naturally occurring obese diabetes.
    Jia DM, Tabaru A, Nakamura H, Fukumitsu KI, Akiyama T, Otsuki M.
    Metabolism; 2000 Sep 01; 49(9):1167-75. PubMed ID: 11016899
    [Abstract] [Full Text] [Related]

  • 17. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
    Okuno A, Tamemoto H, Tobe K, Ueki K, Mori Y, Iwamoto K, Umesono K, Akanuma Y, Fujiwara T, Horikoshi H, Yazaki Y, Kadowaki T.
    J Clin Invest; 1998 Mar 15; 101(6):1354-61. PubMed ID: 9502777
    [Abstract] [Full Text] [Related]

  • 18. Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
    Fujiwara T, Wada M, Fukuda K, Fukami M, Yoshioka S, Yoshioka T, Horikoshi H.
    Metabolism; 1991 Nov 15; 40(11):1213-8. PubMed ID: 1943750
    [Abstract] [Full Text] [Related]

  • 19. The transcription factor Fos-related antigen 1 is induced by thiazolidinediones during differentiation of 3T3-L1 cells.
    Albrektsen T, Fleckner J.
    Mol Pharmacol; 2001 Mar 15; 59(3):567-75. PubMed ID: 11179452
    [Abstract] [Full Text] [Related]

  • 20. Troglitazone: the discovery and development of a novel therapy for the treatment of Type 2 diabetes mellitus.
    Parker JC.
    Adv Drug Deliv Rev; 2002 Nov 05; 54(9):1173-97. PubMed ID: 12393300
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.